| INTRODUCTION
Ovarian cancer is the seventh most common cancer in women worldwide. 1 The majority of ovarian cancers are diagnosed at advanced stages. 2 The standard first-line therapy for ovarian cancer is a combination of surgery and carboplatin/paclitaxel-based chemotherapy. However, about 80% of advanced ovarian cancers relapse with more aggressive and drug-resistant disease. 3 The fiveyear survival rate for patients with advanced ovarian cancer remains at less than 30%. 4 There is also an unmet need for therapy which could improve the quality of life in patients with advanced or recurrent ovarian cancer.
The main symptom of advanced ovarian cancer in patients is accumulation of ascites. Recent molecular therapy research has primarily focused on the tumor microenvironment. The tumor microenvironment changes over the course of cancer progression and influences metastasis as a dynamic process. The detailed mechanisms underlying malignant ascites and tumor progression in the ovarian cancer tumor microenvironment have been elucidated. Our previous study showed that in epithelial ovarian cancer ascites, cell-
to-cell interactions between tumor cells and macrophages led to
Stat3 activation of both cell types. 5 Stat3 activation in the cancer cells enhanced cell proliferation and induced production of interleukin (IL)-6 and IL-10 by macrophages. Another study showed that M2-like macrophages promote spheroid formation and tumor metastases in ovarian cancer. 6 It is well known that macrophages are derived from monocytes. M1-like macrophages act as antitumor effector cells, whereas M2-like macrophages act as suppressors of antitumor immune responses by producing immunosuppressive cytokines, including IL-6, IL-10, and transforming growth factor β (TGF-β). 7 Over the past decades, interferon (IFN)-β has received considerable attention for the treatment of various cancers. It has been reported that IFN-β either inhibits tumor cell proliferation or induces apoptosis of tumor cells through the Jak-Stat1 intracellular signaling pathway. Activation of the host antitumor immune system and suppression of tumor angiogenesis by IFN-β has also been described. 8, 9 However, the successful use of IFN-β as an anticancer agent is limited to therapy for melanoma, hairy cell leukemia, chronic myelogenous leukemia, renal cell cancer and brain tumors. This restricted efficacy of IFN-β may be as a result of its short half-life and rapid clearance from the circulation after i.v. injection. In addition, systemic toxicity precludes high-dose administration. In the present study, we developed an orthotopic xenograft model of dissemination of intraperitoneal ovarian cancer. Using this system, we evaluated the effect of iPS-ML/IFN-β on cancer progression and retention of ascites.
| MATERIALS AND METHODS

| Cell lines and culture conditions
Human ovarian cancer cell lines SKOV3, ES2, A2780 and SW626
were provided by ATCC (Manassas, VA, USA). SKOV3 and ES2 cells were transduced with a lentivirus vector encoding firefly luciferase.
These cells were maintained in RPMI-1640 medium (Wako Pure Chemical Industries, Osaka, Japan) supplemented with 10% FBS, 100 IU/mL penicillin G and 100 μg/mL streptomycin at 37°C in a fully humidified 5% CO 2 incubator. The methods used for the generation of iPS-ML producing a large amount of human IFN-β will be described elsewhere manuscript in preparation. iPS-ML and iPS-ML producing IFN-β (iPS-ML/IFN-β) were maintained in α-MEM containing 20% FBS. 
| Clinical samples
| MTS assay
| Luciferase assay
| Flow cytometric analysis
We analyzed the expression of cell-surface molecules on non-IFNproducing iPS-ML and iPS-ML/IFN-β by a flow cytometric analysis.
The following mAbs conjugated with phycoerythrin were purchased (Bio-Rad/DAKO, Hercules, CA, USA). The methods used for immunohistochemical analysis of rat anti-CD204 have been described previously. 16 After rinsing, the samples were incubated with HRPlabeled polymer and the immunoreaction was visualized using a DAB substrate system. 
| Immunohistochemical analysis
| Xenograft ovarian cancer model
| Statistical analysis
Statistical analyses were carried out using Student's t test (SPSS version 24, IBM; Armonk, NY, USA). A P-value of <0.05 was considered statistically significant.
| RESULTS
| Sensitivity of ovarian cancer cell lines to IFN
We examined the sensitivity of four human ovarian cancer cell lines Figure S1 ). According to these findings, it is confirmed that iPS-ML had no direct anticancer effect.
| Cognate interaction of tumor cells and macrophages
Direct interaction between macrophages and cancer cells plays a pivotal role in tumor progression. We previously reported the existence 
| Therapeutic effect of iPS-ML/IFN-β in xenograft models
We injected SKOV3 cells expressing luciferase into the peritoneal cavity of SCID mice to establish a peritoneal dissemination model that we could use to quantitatively monitor in vivo cancer progression by imaging. After confirmation of the engraftment of the tumor, we divided the mice into treatment and control groups. We injected iPS-ML/IFN-β i.p. into the mice of the treatment group twice each week.
Luminescence image analysis showed a continuous progression of tumors from day 3 to day 24 in the mice of the control group. In contrast, tumor progression was inhibited in the mice of the treatment group ( Figure 4A,B) . The difference in tumor progression at day 24 between the treatment and control groups was statistically significant (P < 0.01).
We killed the mice on day 31 and isolated the tumors. Tumor weights from the mice in the control and treatment groups were 0.54 ± 0.12 g and 0.11 ± 0.06 g, respectively (P < 0.01; Figure 4C ).
Tumor progression in the mice was accompanied by abdominal distension as a result of the retention of ascites. This distension is similar to that seen clinically in patients with advanced ovarian cancer. We measured the volume of ascites on day 31. The volume of ascites was more than 2 mL/mouse on average in the control group, whereas ascites were not detected in the mice of the treatment group ( Figure 4D ). Giving non-IFN-producing iPS-ML did not affect the disseminated tumors of SKOV3 cells in the model mice ( Figure S2 ).
Collectively, therapy with iPS-ML/IFN-β significantly suppressed tumor progression in SCID mice intraperitoneally engrafted with human ovarian cancer cells. In addition, the retention of ascites caused by the cancer was dramatically inhibited by the treatment.
| Infiltration of iPS-ML/IFN-β into tumor tissues
Infiltration of macrophages is observed in various types of cancer tissues. We had expected that iPS-ML/IFN-β given to cancer-bearing mice for therapeutic purposes would also infiltrate into the cancer.
To examine this expectation, we histologically analyzed the tumor We previously noted that the number of live iPS-ML/IFN-β rapidly decreased after their injection into SCID mice. 15 The number of iPS-ML/IFN-β might have been higher at an earlier time point, and the small number of iPS-ML/IFN-β detected in the tumor tissues (Figure 5E ,F) might reflect their subsequent decay in vivo. In any case, we observed that iPS-ML/IFN-β injected into the tumor-bearing mice in our xenograft model migrated into the ovarian cancer tissues. the mice underwent a luminescence imaging analysis to evaluate the development of ovarian cancer metastases. After confirmation of the engraftment of the cancer, the mice were divided into a treatment (n = 5) and a control (n = 5) group. The mice in the treatment group were injected with iPS-ML/IFN-β (1 × 10 7 cells/mouse) twice each week, whereas those in the control group were left untreated. A, Tumor progression was monitored every week, using in vivo luminescence imaging analysis. B, The change in the luminescence signal in mice was calculated as a relative value, with the luminescence activity on day 3 defined as 1. Orange line and blue line in the graph indicate the control (no therapy) and iPS-ML/IFN-β-treated mice, respectively. The imaging analysis was conducted twice. C,D, Three days after the last therapy and luminescence analysis (on day 31), the mice were killed and subjected to laparotomy to collect ascites and tumors, and the weight of tumors (C) and the volume of ascites (D) of each mouse was measured. Data shown are the mean ± SD of each mouse group. The difference from the control group was statistically significant (*P < 0.05; **P < 0.01 by Student's t test) previously been described. In the current study, we evaluated a strategy to use iPS-ML as a cell-based drug-delivery system to make 
